|
Bruce
Hammock, Ph.D.
Edmund
Capparelli, Pharm. D.
James
Harris, Ph.D.
John Vogel, Ph.D.
Luis
Ruzo, Ph.D.
Dr. Vogel
was,
until 2005, a Senior Scientist at the Center for Accelerator Mass
Spectrometry at Lawrence Livermore National Laboratories (LLNL). He is distinguished as the founder and most recognizable
proponent of biological Accelerator Mass Spectrometry. Dr.
Vogel has published 100's of scientific papers in the field of AMS
including its key foundation papers that described the technical
aspects of biological AMS. As
a speaker, he is in high demand and is regularly invited to address
key international meetings on topics ranging from AMS machinery to
biomedical topics that been advanced from the unique capabilities of
AMS. He maintains an Adjunct Professorship in the Department
of Nutrition at University of California , Davis.
Dr. Vogel holds several key patents in AMS technology,
including applications in biomedical research.
Dr. Hammock is a distinguished
Professor of Entomology & Cancer Research Center and Director of
NIEHS-UCD Superfund Basic Research Program at University of
California, Davis. Dr. Hammock’s research efforts have had an
exemplary impact on many different areas of biology, agriculture and
medicine. He has received numerous academic awards including the
prestigious Alexander von Humboldt Award in 1995 for his research
contributions to U.S. agriculture and the Burroughs Welcome
Toxicology Scholar Award from the Society of Toxicology in 1987. He
was elected in 1999 to the National Academy of Sciences, one of the
highest honors for scientists in the United States.
He was an original adopter of AMS technology and has
published many of the
fundamental papers on applied AMS.
Dr. Harris is a Co-founder and
Chief Scientific Officer of Bioavailability Systems (BAS) and the
sole inventor of all BAS patents. From 1991 to 1996, Dr. Harris
worked for the FDA, Center for Drug Evaluation and Research,
ultimately becoming a key member in clinical pharmacology research.
During that time he published papers on the elucidation of the
metabolism of Taxol™ by CYP 3A and the isolation of the principal
Taxol™ metabolite. Dr. Harris earned an MS and a PhD in Toxicology
from the University of Rochester School of Medicine and Dentistry in
1989 and 1991 respectively, and a BS in Chemistry from Vanderbilt
University in 1987.
Dr. Capparelli,
Director, Pediatric Pharmacology Research Unit (PPRU) &
International Maternal, Pediatric and Adolescent AIDS Clinical
Trials (IMPAACT) Network Pharmacology Laboratory; Clinical
Professor, Pediatrics Division of Pharmacology and Drug Discovery
School of Medicine, Department of Pediatrics and Skagg's School of
Pharmacy & Pharmaceutical Sciences University of California, San
Diego, will assist Vitalea in the development of tools for pediatric
clinical pharmacology using Accelerator- technology, and
particularly in applications in clinical trials of treatments of
HIV/AIDS and related infections in pediatrics. Dr.
Capparelli received his PharmD degree from the University of
California, San Francisco in 1985 and completed Fellowships at
Hartford Hospital, Connecticut in 1987 and the University of
California, Irvine in 1988. In 1992, he helped secure NIH support
for the UC San Diego Pediatric Pharmacology Laboratory to support
the Pediatric AIDS Clinical Trials Group (ACTG) and in 1994
co-founded the National Institute of Childhood Health and Human
Development supported UC San Diego-Children's Hospital Pediatric
Pharmacology Research Unit (PPRU). He has served in leadership roles
in both of these networks including chair of the Pediatric ACTG
Pharmacology Committee from 2002 through 2004. Dr. Capparelli
continues to co-direct these programs as well as direct clinical
pharmacology sections of other multi-center NIH sponsored studies.
Dr. Capparelli is board certified in Applied Pharmacology and holds
appointments with both the UC San Diego School of Medicine and UC
San Francisco School of Pharmacy. He is recognized for his work in
applying population pharmacokinetic methods in pediatric
populations. Dr. Capparelli has served on several NIH workshop
panels, the editorial board for Antimicrobial Agents and
Chemotherapy and the Advisory Sub-Committee to the FDA in Clinical
Pharmacology, and the World Health Organization expert working group
on Pediatric HIV/AIDS. Dr. Capparelli has published more than 50
papers and book chapters.
Dr.
Ruzo is founder and managing director of PTRL West. PTRL
West is a full service contract research laboratory located in
Hercules, California on the San Francisco Bay. The company was
founded in 1987. Its sister company in Germany, PTRL Europe, has
been in operation since 1992. PTRL West conducts studies needed to
satisfy regulatory requirements in the areas of environmental fate,
metabolism, and analysis of agrochemicals, industrial chemicals and
pharmaceuticals. Dr. Ruzo provides insight and market penetration
into the enviromental/agrochemical testing area for which Vitalea's
technology is well suited. |
|
|
|
|
